186 related articles for article (PubMed ID: 8422670)
1. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
[TBL] [Abstract][Full Text] [Related]
2. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
3. [New mucin core protein genes and their clinical application].
Imai K
Hokkaido Igaku Zasshi; 1996 Mar; 71(2):139-43. PubMed ID: 8641670
[TBL] [Abstract][Full Text] [Related]
4. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
5. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
[TBL] [Abstract][Full Text] [Related]
6. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
[TBL] [Abstract][Full Text] [Related]
7. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.
Acres RB; Hareuveni M; Balloul JM; Kieny MP
J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):136-43. PubMed ID: 8280702
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
12. [Molecular biological analyses of mucin core proteins and their clinical application].
Hinoda Y; Imai K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):150-6. PubMed ID: 8311484
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
14. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
15. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC
Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097
[TBL] [Abstract][Full Text] [Related]
16. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity of MUC1 peptides and fusion protein.
Apostolopoulos V; Pietersz GA; Xing PX; Lees CJ; Michael M; Bishop J; McKenzie IF
Cancer Lett; 1995 Mar; 90(1):21-6. PubMed ID: 7720038
[TBL] [Abstract][Full Text] [Related]
18. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
